IDN-13389

IDN-13389 is a preclinical small-molecule oncology drug candidate originally developed by Idun Pharmaceuticals and later acquired by Conatus Pharmaceuticals as part of Idun’s apoptosis-focused pipeline. Publicly available information describes IDN-13389 only as an oncology candidate within Idun’s portfolio of apoptosis-modulating agents, but its precise molecular target, mechanism of action, structure, and specific tumor indications have not been disclosed. The asset was at the preclinical stage at the time of Idun’s acquisition and there is no evidence it advanced into clinical trials or regulatory development afterward.